COSCIENS Biopharma shares are trading lower after the company announced results from its Phase 3 DETECT-Trial of AEZS-130-P02. The primary endpoint was not met.
Portfolio Pulse from Benzinga Newsdesk
COSCIENS Biopharma's shares fell after the company announced that its Phase 3 DETECT-Trial of AEZS-130-P02 did not meet the primary endpoint.
August 27, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
COSCIENS Biopharma's Phase 3 DETECT-Trial of AEZS-130-P02 failed to meet its primary endpoint, leading to a decline in share prices.
The failure to meet the primary endpoint in a Phase 3 trial is a significant setback for any biopharma company, as it can delay or prevent the drug from reaching the market. This news likely led to a decrease in investor confidence, resulting in a drop in share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100